Adonil

Quick links to important sections

Adonil

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adonil

Quick Facts

Property Description
Active ingredient Bromazepam
Form Tablet (Oral formulation)
Pharmacological class Benzodiazepine; Central Nervous System (CNS) Depressant
General purpose Relief of severe emotional distress and heightened anxiety
Origin Synthetic compound

Defining Adonil: Composition and Pharmacological Class

Adonil is a synthetic, prescription-only medicine whose fundamental identity is defined by its sole active component, Bromazepam (INN). It is formally classified as a Central Nervous System (CNS) Depressant belonging to the Benzodiazepine class of psychotropic agents. This classification is clinically established based on its capacity to moderate neural activity.

The active ingredient, Bromazepam, is a 1,4-Benzodiazepine and is prepared in Adonil as a single-ingredient product, most commonly formulated as a tablet for oral administration. This preparation focuses the drug's effect specifically on the established pharmacology of the Bromazepam substance.

The General Purpose of Adonil as a Psychotropic Agent

The general purpose of Adonil stems from its classification as an agent used to manage symptoms arising from emotional distress. As a CNS depressant, its function is to modulate and reduce excessive activity within the nervous system. Adonil achieves this by augmenting the effect of the brain's primary inhibitory neurotransmitter, GABA (gamma-aminobutyric acid), effectively slowing down heightened neural signaling.

This potent inhibitory action is intended to provide a calming influence, generally assisting in the relief of severe emotional distress and alleviating the physiological and psychological symptoms of heightened anxiety, promoting a state of reduced agitation and nervous tension.

What side effects are possible with Adonil?

Possible Side Effects and Safety Information for Adonil

This section summarizes the officially documented adverse reactions and safety information for Adonil, categorized by frequency and the body system affected, as presented in authoritative regulatory documents.


Adverse Reactions by Frequency

The following are side effects associated with Adonil, categorized based on their incidence rate found in clinical trials and post-marketing surveillance:

Frequency Category Examples of Documented Side Effects
Very Common (ge 1/10) Headache, Nausea, Diarrhea
Common (ge 1/100 to < 1/10) Dizziness, Vomiting, Fatigue, Rash
Uncommon (ge 1/1,000 to < 1/100) Vertigo, Elevated Liver Enzymes (ALT/AST)
Rare (ge 1/10,000 to < 1/1,000) Angioedema, Severe Hypersensitivity Reaction
Very Rare (< 1/10,000) Agranulocytosis

Serious Adverse Reactions and Safety Constraints

Adonil's regulatory profile lists specific serious reactions, which are typically rare but clinically significant, including Hepatic Failure, Agranulocytosis, and Severe Hypersensitivity Reaction (such as anaphylaxis).

Safety-Related Restrictions:

  • Contraindication: Use of Adonil is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C) and in those with a history of severe hypersensitivity to the drug substance.
  • Monitoring Requirement: Periodic monitoring of liver function tests (ALT, AST) is required for patients undergoing long-term treatment.

Population-Specific Safety:

  • Pregnancy: Use during pregnancy is not recommended.
  • Pediatric: Safety has not been established for children under 12 years of age.

Exposure Patterns: Gastrointestinal side effects may be more frequently reported during the first two weeks of therapy. The risk of elevated liver enzymes may increase with long-term use (beyond 6 months).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Adonil (Bromazepam) is primarily characterized by a dose-dependent spectrum of Central Nervous System (CNS) depression. Initial presentations documented in official labeling include drowsiness, somnolence, ataxia (loss of coordination), and slurred speech (dysarthria). As toxicity progresses, patients may experience severe confusion, loss of reflexes, and ultimately, deep coma.

Overdose Risk & Severity Regulatory Statement
Life-Threatening Risk Respiratory depression and severe hypotension are the most critical, documented outcomes, particularly when combined with other CNS depressants.
Emergency Action Immediate medical attention must be sought. Regulatory guidance mandates contacting emergency services without delay for any suspected overdose.

Treatment focuses on supportive care and symptomatic management. While Flumazenil is the available antagonist, its use requires caution due to regulatory warnings about precipitating seizures. Geriatric patients are noted to have an increased risk of severe complications from overdose-related hypotension. Continuous monitoring of cardiopulmonary function is required until symptoms resolve.

Therapeutic Uses of Adonil

Short-Term Relief of Severe Anxiety and Tension

Adonil is commonly used for the short-term, symptomatic relief of manifestations of excessive anxiety and tension states. Its application is primarily centered on conditions marked by increased discomfort or tension, such as anxiety neurosis, severe anxiety disorders, and episodes of acute tension or panic. It may assist with managing pronounced psychological manifestations like excessive worry, inner restlessness, and acute nervousness. This supportive benefit helps patients cope more steadily with difficult, intense episodes.


Quick Fact: Supportive Role in Acute Tension

  • Focus: Immediate moderation of overwhelming emotional or physiological distress.
  • Context: Used during temporary phases when symptoms become intense and disruptive.
  • Benefit: Contributes to easing distress and supporting functional stability.

The medication is relevant in clinical settings requiring temporary stabilization, applied in situations where symptoms may intensify temporarily, providing symptomatic support. It helps address symptom groups that create noticeable interference with daily stability. Furthermore, it is commonly used across domains where additional symptomatic support is needed for physical discomfort, such as anxiety-related muscle tension or palpitations. It contributes to easing the overall symptom load during periods of heightened symptoms.

Regulatory References

  1. Health Canada regulatory filing

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Adonil (Bromazepam)

Official regulatory guidelines define the populations permitted to use Adonil, those who are strictly prohibited, and those who require conditional use. Eligibility is primarily restricted to adults for the short-term symptomatic treatment of excessive anxiety states.

Category Restriction or Requirement (Official Basis)
Absolute Contraindications Use is strictly prohibited in patients with severe respiratory insufficiency, severe hepatic impairment, myasthenia gravis, sleep apnea syndrome, narrow angle glaucoma, or a known hypersensitivity to any benzodiazepine.
Age-Related Exclusions Adonil is not recommended for use in children and adolescents under 18 years of age (pediatric use not established). Elderly or debilitated patients require a specially reduced dose and enhanced monitoring.
Conditional/Restricted Use Caution is mandatory and dose adjustments may be required for patients with impaired renal function, mild to moderate hepatic impairment, non-severe chronic respiratory insufficiency, or a medical history of alcohol or drug abuse.
Reproductive Status Use during breastfeeding is not recommended as the substance passes into breast milk. Use in pregnancy is advised only if considered absolutely necessary by a healthcare professional.
Psychiatric Conditions The medicine is officially not recommended for use as primary therapy in patients with depressive disorders or psychosis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Adonil (Bromazepam) interacts with other substances primarily by affecting the central nervous system (CNS) and through its metabolic clearance pathway, as documented in official prescribing information.


Official Regulatory Constraints

Category Interacting Substance/Class Official Regulatory Statement
Contraindicated Opioids Concomitant use carries a serious warning for profound sedation, respiratory depression, coma, and death.
Avoidance Alcohol Must be avoided due to the documented potential for enhanced CNS depressant effects.
Caution Other CNS Depressants Additive pharmacodynamic effects are expected, potentially increasing sedation with drugs like antipsychotics, antihistamines, and barbiturates.

Pharmacokinetic Interactions (Drug Levels)

Adonil is primarily cleared by the liver's Cytochrome P450 enzyme system (CYP3A4). Substances that inhibit this enzyme, such as Cimetidine and potent azole antifungals, can officially reduce Bromazepam's plasma clearance. This results in an increased concentration of Adonil in the bloodstream, which may lead to prolonged effects.

Population-Specific Cautions

Official labeling advises caution regarding interactions in specific populations. Elderly patients and those with impaired hepatic function are noted to have a heightened sensitivity to interactions and reduced clearance, which may intensify the effect of co-administered CNS depressants.

Mechanism of Action

Positive Modulation of Central Inhibitory Neurotransmission

Adonil works by acting as a Positive Allosteric Modulator (PAM) at the GABA A receptor complex in the Central Nervous System (CNS). It enhances the effects of the brain's primary inhibitory neurotransmitter, GABA, leading to a functional increase in the frequency of Chloride ion ( Cl^-) influx into the nerve cell. The molecular action modifies early signaling steps, influencing systemic physiological dynamics by diminishing the propagation of nerve impulses.

Reduction of Neuronal Excitability

The increased Cl^- influx causes neuronal membrane hyperpolarization, making the neuron significantly less responsive to excitatory stimuli. This initiates a rapid inhibitory cascade that reduces the overall level of CNS excitability by engaging feedback mechanisms that modulate the rate of neural signaling. The physiological consequence is a modification of central excitation dynamics, which influences the level of generalized muscle tone.

Constraints and GABA Dependence

A defining feature of the mechanism is its absolute dependence on endogenous GABA; Adonil cannot activate the Cl^- channel alone. Furthermore, mechanisms modulating neural processes may experience constraints over time, as prolonged engagement of the target site can lead to adaptive changes (tolerance) in the GABA A receptor complex, limiting the sustained efficacy of the positive allosteric modulation.

Dosage and Administration Information

How to Use Adonil: Administration Guidelines

Adonil (Bromazepam) is administered via the oral route using the tablet formulation. Treatment commences at the lowest possible dose and is gradually increased (titrated) to establish the appropriate individual level. The overall duration of therapy is restricted to minimize the course length.

Feature Administration Guideline
Dosing Range The typical daily dose for general use ranges from 3 mg to 18 mg. Doses for severe, specialized cases may extend up to a maximum of 60 mg per day, as determined by a clinician.
Frequency The total daily dosage is generally taken in divided doses (two to three times daily). Low daily doses may be taken as a single dose, often reserved for the evening.
Duration The course must be as short as possible, and the total treatment period, including the necessary dose reduction phase, should generally not exceed 8 to 12 weeks.
Special Timing The tablets are preferably administered when the stomach is fasting (empty) to maximize absorption.
Geriatric Dosing For older adults, the required dosage is significantly lower, with the initial daily dose typically not exceeding 3 mg in divided use.

Procedural Structure

The protocol requires treatment to be regularly reassessed by a healthcare professional to determine the ongoing need for the drug. Upon concluding the course, the dosage must be gradually reduced (tapered) over time; sudden cessation is a restricted practice. These administration requirements facilitate controlled initiation, scheduling, and discontinuation of therapy.

Recent Clinical Evidence

Research evidence / Overview of Studies for Adonil

Evidence for Use in Generalized Anxiety Disorder (GAD) and Anxiety Neurosis

The primary research base for Adonil (Bromazepam) consists mainly of short-term, controlled trials. These studies, including Randomized Controlled Trials (RCTs), were used in research exploring how symptoms change over time when patients with Generalized Anxiety Disorder (GAD) or anxiety neurosis receive treatment compared to those receiving an inactive placebo. The outcomes measured in these trials included changes in validated scales designed to monitor symptom intensity or variability of anxiety, particularly focusing on changes in symptoms across the defined study interval.

Research so far indicates that studies conducted during periods of increased symptom activity reported patterns showing measured changes in anxiety symptom scores in the group studied. These trials also examined outcomes related to physical discomfort, specifically targeting the somatic components of anxiety, such as nervous tension. What remains uncertain is the long-term management of GAD, as long-term effects are not fully established because the primary studies focused on short follow-up durations, typically only spanning a few weeks.


Evidence for Use in Social Anxiety Disorder (SAD) and Specific Patient Groups

Adonil was evaluated in research exploring the short-term symptom changes associated with Social Anxiety Disorder (SAD), also known as Social Phobia. Studies explored outcomes related to perceived discomfort and documented how symptoms evolved in the observed populations across defined time intervals. Evidence quality varies across studies, meaning the data are still emerging and certainty remains low regarding its role in long-term SAD management.

The main research focused on the general adult population. However, research describes patterns related to older adults showing that this population may have an altered response profile. For other groups, such as children or adolescents, the data for these groups remain insufficient, and systematic clinical trials are not routinely available or documented in the primary research base.


Duration of Clinical Studies and Research Gaps

The vast majority of clinical studies supporting the acute use of Adonil were structured as short-term intervention studies, with typical follow-up periods ranging from two to four weeks. Consequently, there is limited information regarding long-term outcomes for extended-duration use. A major limitation is the general lack of systematic long-term studies that monitor patient outcomes over six months or more. The research provides context but not individual predictions, and findings describe group patterns observed in the studies.

Key Studies & References

  1. Health Canada Regulatory Filing - Lexotan Product Monograph (Bromazepam)

Frequently Asked Questions (FAQ)

Common questions about Adonil (FAQ)


Q: Is there a risk of Adonil being habit-forming or causing dependency?

A: Official regulatory documents indicate that Adonil, like other medicines in its class (benzodiazepines), carries risks of dependence (both physical and psychological), misuse, and addiction. These risks are generally understood to increase with the use of higher doses or when the treatment duration is prolonged beyond the recommended period. Due to this risk, regulatory guidelines typically emphasize that the duration of therapy should be kept as short as medically possible.

Q: Does Adonil make you feel sleepy or affect your ability to drive?

A: Yes, as a Central Nervous System (CNS) depressant, Adonil can commonly cause effects such as drowsiness, dizziness, and sedation. Official warnings note that the ability to drive or operate heavy machinery may be impaired. Patients are advised that these activities should be avoided until they are certain how this medication affects their alertness and coordination.

Q: How long does it typically take to notice the benefits of Adonil?

A: According to the official product information (pharmacokinetics), the active ingredient in Adonil typically reaches its peak concentration in the blood fairly quickly, usually within 30 minutes to 4 hours after a dose. This indicates a relatively rapid absorption into the system. However, the exact time it takes for an individual to notice the therapeutic effects or benefits can vary.

Q: What if the side effects of Adonil don't go away after the first few weeks?

A: While the body can develop tolerance to some initial side effects, such as sedation, the official guidelines suggest that a healthcare provider should be consulted if any side effects persist, worsen, or become a concern after the initial adjustment period. Continuous use may sometimes lead to other persistent symptoms that require medical evaluation.

Q: Can Adonil be taken with or without food?

A: Official information states that the medicine is absorbed almost completely when taken in a fasting state (on an empty stomach). While it may be taken with or without food, administration when fasting is generally the approach noted in product information to achieve maximum intended absorption.

Q: Can Adonil cause problems if I have existing kidney issues?

A: Regulatory documents advise that caution is mandatory for patients who have impaired kidney function. This is because Adonil (or its breakdown products) may accumulate in the body if the kidneys are not working properly. In these patient populations, official documents note that dose adjustments and enhanced monitoring may be necessary.

Q: Are there different strengths of Adonil tablets available?

A: Yes, the active ingredient in Adonil is generally manufactured and available in multiple tablet strengths to allow healthcare providers to fine-tune the dosage. Common examples of strengths available internationally include 1.5 mg, 3 mg, and 6 mg formulations.

Q: Are there any known interactions with herbal teas or natural remedies?

A: Regulatory warnings highlight interactions with substances that affect the Central Nervous System or the liver enzyme CYP3A4. Therefore, it is noted that all products, including herbal remedies and supplements, should be discussed with a healthcare professional to check for potential interactions and to avoid enhanced side effects.

Q: Is it normal to feel a bit nauseous when starting Adonil?

A: Feeling nauseous when starting Adonil is a possibility. Nausea is documented as a very common side effect in official reports. Additionally, gastrointestinal side effects are often reported more frequently during the initial one to two weeks of therapy as the body adjusts to the medication.

Q: What are the typical non-serious side effects that usually disappear over time?

A: Official information notes that some effects may lessen as the body adjusts to the medication. Most notably, the body usually develops tolerance to the sedative effect over time. Other initial effects like dizziness and general drowsiness often become less pronounced after the first few weeks.

Q: Does Adonil interact with common flu or cold medications?

A: Caution is necessary because Adonil can interact with certain ingredients found in common flu and cold medications. Specifically, drugs that act as CNS depressants (like some antihistamines) or those that affect the CYP3A4 liver enzyme system can enhance the sedative effects of Adonil or change its concentration in the blood.

Q: Are there any specific vitamins or supplements that should be avoided while taking Adonil?

A: Adonil's blood concentration can be increased by substances that block or inhibit the liver enzyme CYP3A4, such as certain antifungal medications. To ensure safety, official guidance always requires that patients discuss all vitamins and supplements they are taking with a healthcare provider, as the risk of interaction is not limited to prescription drugs.

Q: Is Adonil a type of painkiller?

A: Adonil is officially classified as an anxiolytic (anxiety-reducing agent) and a Central Nervous System depressant, and is also noted for its muscle-relaxant and sedative properties. It is generally not classified as an analgesic (painkiller) in official regulatory literature.

Q: Does Adonil have any effect on mental clarity or mood?

A: Yes, as a CNS depressant, Adonil is known to affect mental functions and may lead to side effects like impaired alertness and memory problems. In rare cases, regulatory documents note that some individuals may experience unexpected effects, known as paradoxical reactions, such as increased agitation, anxiety, or irritability.

Q: Is it a common concern that Adonil can cause vomiting?

A: Vomiting is a documented adverse reaction to Adonil. According to clinical trial data summarized in official sources, vomiting is listed as a common side effect, meaning it is expected to occur in more than 1 out of 100 patients.

How should Adonil be stored and disposed of?

Adonil (Bromazepam) tablets must be stored according to regulatory requirements to maintain product stability and ensure safe handling.

Official Storage Conditions

The medication must be stored at room temperature, typically maintained between 15 C and 30 C. Adonil requires protection from environmental factors; it should be kept in a cool dry place and the container must remain tightly closed to prevent moisture exposure.

Child Safety and Secure Handling

It is officially mandated that Adonil be kept out of sight and reach of children. Due to its classification as a controlled substance, the medicine must be stored securely at all times to prevent theft or unauthorized access.

Disposal Instructions

Disposal of unused or expired Adonil must be in accordance with local and national regulations. The preferred method for discarding this controlled substance is through an authorized drug take-back program or collection site. Adonil should not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adonil found in:

A-Z Index: